CIK: 0001910456 · Show all filings
Period: Q2 2023 (← Previous) (Next →)
Filing Date: Aug 14, 2023
Total Value ($000): $152,625 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | MERUS N V | 1,152,525 | $30,346 | 19.9% | $24.66 | — | COM | N5749R100 |
| CABA | CABALETTA BIO INC | 2,181,377 | $28,162 | 18.5% | $3.64 | +198.1% | COM | 12674W109 |
| — | ALPINE IMMUNE SCIENCES INC | 2,670,472 | $27,452 | 18.0% | $10.20 | — | COM | 02083G100 |
| — | CYMABAY THERAPEUTICS INC | 1,205,050 | $13,195 | 8.6% | $3.16 | — | COM | 23257D103 |
| TCRX | TSCAN THERAPEUTICS INC | 5,224,600 | $13,062 | 8.6% | $2.68 | 0.0% | COM | 89854M101 |
| GHRS | GH RESEARCH PLC | 969,374 | $11,502 | 7.5% | $10.26 | 0.0% | ORDINARY SHARES | G3855L106 |
| — | PARDES BIOSCIENCES INC | 3,902,434 | $7,063 | 4.6% | $5.14 | — | COM | 69945Q105 |
| — | THESEUS PHARMACEUTICALS INC | 757,009 | $7,063 | 4.6% | $8.59 | — | COM | 88369M101 |
| — | KINNATE BIOPHARMA INC | 2,048,736 | $6,208 | 4.1% | $10.62 | — | COM | 49705R105 |
| — | NEOLEUKIN THERAPEUTICS INC | 3,094,554 | $2,568 | 1.7% | $0.59 | — | COM | 64049K104 |
| — | PIERIS PHARMACEUTICALS INC | 9,775,849 | $1,618 | 1.1% | $1.23 | — | COM | 720795103 |
| CGEM | CULLINAN ONCOLOGY INC | 115,063 | $1,238 | 0.8% | $10.62 | 0.0% | COM | 230031106 |
| — | PASSAGE BIO INC | 1,167,343 | $1,099 | 0.7% | $1.43 | — | COM | 702712100 |
| GPCR | STRUCTURE THERAPEUTICS INC | 23,000 | $956 | 0.6% | $23.79 | — | SPONSORED ADS | 86366E106 |
| — | ATHIRA PHARMA INC | 193,573 | $571 | 0.4% | $2.95 | — | COM | 04746L104 |
| PHVS | PHARVARIS N V | 21,225 | $321 | 0.2% | $5.38 | +79.0% | COM | N69605108 |
| CMPS | COMPASS PATHWAYS PLC | 20,114 | $167 | 0.1% | $8.28 | — | SPONSORED ADS | 20451W101 |
| — | DBV TECHNOLOGIES S A | 18,265 | $35 | 0.0% | $1.90 | — | SPONSORED ADR | 23306J101 |